Testing effectiveness (Phase 2)Active Not RecruitingNCT06680622
What this trial is testing
Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy
Who this might be right for
Metastatic Gastro-esophageal Adenocarcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 126